Association Between Retroperitoneal Lymphadenectomy and Survival Benefit in the Endometrioid-Type Endometrial Carcinoma Patients

Uterine cancer stays the most prevalent gynecologic malignancy in developed countries. Providing suitable solutions to treat this disease is required to the early diagnosis of this cancer. The aim of this study was to evaluate the effectiveness of multiple-site lymph node sampling in patients with the endometrioid type of endometrial cancer. Demographic and clinicopathologic data were obtained from the Tehran Gynecology Oncology ward in Vali-e-Asr Hospital between 1999 and 2010. All the patients were divided into two groups. Group A (n = 102): patients who underwent multiple-site lymph node sampling; and Group B (n = 102): patients who did not undergo multiple-site lymph node sampling. Survival curves were calculated using the Kaplan-Meier method, and the differences in survival rates were analyzed using the log-rank test. The median age was 55 years (range = 18 - 84). The 5-year progression-free survival rates of Groups A and B were 85% and 87%, respectively (P = 0.456). In addition, the 5-year overall survival rates were 95% and 93.9%, respectively (P = 0.651). Subsequently, there was no significant difference in recurrence rates in retroperitoneal lymph nodes regardless of the completion of lymphadenectomy. The obtained data showed no evidence of benefit in terms of overall or recurrence-free survival for pelvic lymphadenectomy in women with early endometrial cancer.